How BioNTech went from a little-known biotech company to creating the Covid vaccine

Business

In this article

It was Jan. 24, 2020 when BioNTech CEO Uğur Şahin knew that Covid-19 was likely to become a global pandemic. 

Though it was over a month and a half before the World Health Organization officially declared a pandemic, Sahin met with his wife, BioNTech’s co-founder and chief medical officer Özlem Türeci. Together, they agreed to redirect most of the company’s resources to developing a vaccine. 

“He approached me and explained his thoughts and his his fears,” Türeci said. “And it was immediately clear to both of us that the technology we had, and which we had already clinically developed, that could help to ensure a rapid response.”

Up until that point, BioNTech was primarily focused on developing novel cancer treatments. The company was little-known internationally. But the founders were confident in the potential of their mRNA technology, which they knew could trigger a powerful immune response. BioNTech knew that to successfully produce, test and manufacture a Covid vaccine on a global scale, it would need a bigger partner. The company already had a relationship with Pfizer, having worked with them since 2018 to develop an mRNA-based flu vaccine, which is in clinical trials. So, BioNTech turned to them.

The companies succeeded. In August, the Pfizer-BioNTech vaccine became the first to gain full FDA approval.

Watch the video to learn about the rise of BioNTech.

Articles You May Like

More than half of shoppers are going into debt this holiday season, study finds
Commerce secretary says U.S. House needs to pass CHIPS Act immediately to ease semiconductor shortage
Auto executives say more than half of U.S. car sales will be EVs by 2030, KPMG survey shows
Top 10 Things To Watch In Commercial Real Estate In 2022
Kay Jewelers parent Signet shares rise after retailer beats expectations and raises outlook

Leave a Reply

Your email address will not be published. Required fields are marked *